Claro Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Claro Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-7	Closed	-$1K	–	180
2018 Q4	$1K	Buy	+7	New	+$538	﹤0.01%	978

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Claro Advisors's ALNY Position: Q1 2019 in Review

Claro Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 7 shares — an estimated $1K sold.

Claro Advisors first reported a position in ALNY in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 290 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

Claro Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 7 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $1K.
Claro Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claro Advisors's Alnylam Pharmaceuticals position peaked at $1K in Q4 2018.
290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.